McKesson Defends Right To $7M Of Disputed Orexigen Funds
Drug distributor McKesson Corp. and a subsidiary reiterated their belief that they are entitled to $7 million in disputed funds being held by debtor Orexigen Therapeutics Inc. in its Delaware Chapter 11...To view the full article, register now.
Already a subscriber? Click here to view full article